Atrial Fibrillation, Diabetes And Anticoagulation With Direct Oral Anticoagulants: Time To Reconsider Duration Of The Disease To Evaluate The Bleeding Risk?

Atrial fibrillation and diabetes: time to reconsider duration of the disease to evaluate the bleeding risk? Impact of diabetes status in patients suffering of non-valvular atrial fibrillation requiring anticoagulation have been analysed previously and risk/benefit balance of NOACs have been confirmed in these patients. The implication of that pathology in the evaluation of the thrombotic risk is discussed but more importantly bleeding risk in this growing population is analysed, perhaps neglected until now.